---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-26-000011"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2026-09-28T20:05:14+00:00"
generated_at: "2026-10-12T13:34:48.702213+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Humacyte adds Scott Coward and Paul Kuznik to board ahead of planned ATEV dialysis launch

## Summary
- Board appointed Scott Coward (Class I, term to 2028, Audit Committee) and Paul Kuznik (Class II, term to 2029, Commercial Committee) on September 22, 2026.
- Coward was EVP, Chief Legal Officer and CAO of Exact Sciences from January 2015 to December 2022 and led the Genomic Health integration; he has been an attorney at K&L Gates since July 2026.
- Kuznik was CEO of Bolton Medical (2015-2018) through its acquisition by Terumo, then President of Terumo Aortic North America from 2020 to 2023.
- Each director receives a $50,000 annual cash retainer, $5,000 per committee, and an option for 125,000 HUMA shares under the non-employee director program.
- CEO Laura Niklason cited the additions as Humacyte expands the Symvess launch and prepares the ATEV commercial launch for dialysis access.

## SEC filing metadata
- accession: 0001818382-26-000011
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2026-09-28T20:05:14+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838226000011/0001818382-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838226000011/huma-20260922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-26-000011
- JSON: https://secwatch.observer/filing/0001818382-26-000011.json
- Plain text: https://secwatch.observer/filing/0001818382-26-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.